Right Value Drug Stores, LLC, dba Carie Boyd's Prescription Shop, Irving, TX
Is Right Value Drug Stores, LLC, dba Carie Boyd's Prescription Shop an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Right Value Drug Stores, LLC, dba Carie Boyd's Prescription Shop in Irving, TX, first registered Jul 3, 2019 and most recently registered Sep 8, 2026. FDA lists its last inspection as Sep 8, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Irving, TX
- Initial registration
- Jul 3, 2019
- Most recent registration
- Sep 8, 2026
- Last inspection
- Sep 8, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 30 numbered observations in all, across 4 inspections ending Nov 12, 2019 to Sep 8, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 24, 2026 to Sep 8, 2026: 6 observations
- Firm on the cover
- Right Value Drug Stores LLC, 8400 Esters Blvd Ste 190, Irving, TX 75063-2217
- FEI number
- 3010589333
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, 503B list
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically, your firm failed to perform adequate smoke study videos of the biological safety cabinets (BSC) in room <Redacted B4> in a dynamic state to demonstrate unidirectional airflow and proper environmental controls during actual operating conditions. Your current practice is to perform aseptic filling operations in room <Redacted B4> with <Redacted B4> BSCs <Redacted B4> operating simultaneously. However, the smoke study videos provided, titled "Workers <Redacted B4> ISO 5 Hood During Fill," did not demonstrate that:
• Unidirectional airflow is maintained during simultaneous operation oflb) <-"J BSCs • Air patterns prevent contamination of critical surfaces
• Personnel movements and interventions do not disrupt the aseptic environment
This is a repeat observation.
Observation 2
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, Your he firm fails to perform dissolution testing and hardness/friability testing as part of estradiol pellets batch release. The specification and batch release criteria are limited to potency assay and endotoxin testing. Since 06/01/2025 through this inspection period, approximately 260 of the <Redacted B4> batches of the following products manufactured were released without dissolution or hardness/friability testing.
batches of the following products manufactured were released without dissolution or hardness/friability testing.
NDC Product
Specification
Estradiol 6 mg Pellet (E6) Redacted B4 73271-0010-01
Estradiol 10 mg Pellet (E10)
Estradiol 12.5 mg Pellet (E12.5)
Estradiol 15 mg Pellet (E15)
Estradiol 18 mg Pellet (E18)
Estradiol 20 mg Pellet (E20)
Estradiol 22 mg Pellet (E22)
Estradiol 25 mg Pellet (E25)
Estradiol 37.5 mg Pellet (E37.5)
Estradiol 50 mg Pellet (E50)
Observation 3
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
A. Your Quality Unit failed to implement corrective actions across all affected master batch records. For example, Master Batch Record 5.351 (Testosterone Cypionate 200 mg/mL with Miglyol, 30 mL, version 5) was revised to require documentation of filling and vent needles replaced during filling to address black particulate matter. However, this corrective action was not implemented across all affected master batch records.
• 5.311: Testosterone Cypionate 200 mg/mL with Miglyol
• 5.321: Testosterone Cypionate/ Propionate 200/10 mg/mL with Miglyol
• 5.341: Testosterone Cypionate 200 mg/mL, 5 mL
This is a repeat observation
B. Your Quality Unit failed to approve Annual Product Review (APR) reports by the due dates required by SOP 4. 130.1 , Annual Product Review Periods and Due Dates, version 4. All APR reports due in 2025 were approved after the dates required by the procedure. For example:
• The APR for Estradiol Pellets, covering June 2024 through May 2025, was due in <Redacted B4> 2025 but was not approved until 05/06/2026. ...
Observation 4
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
A. Equipment Calibration: Procedure 2.020, Equipment Calibration, version 4, does not include the requirement to adequately investigate the impact of equipment found out of tolerance. For example:
• The most recent calibration ce1tificates for analytical balances 19-00004 (serial ~(6 (4) I, located in 1(6) (4~ and 19-00013 (serial 6) -(4) j, located in 1(0) (4)1 showed "out of tolerance" results. These balances are used as pait ofpellet compounding and vialing operations. No associated deviation or impact evaluation was perfo1med.
B. Environmental Monitoring: The fnm does not have a clear and robust method for tracking and trending Inicrobial recoveries over time, resulting in inadequate monitoring of the ongoing presence of various molds in the clean rooms. For example:
• Mold recoveries in the pellet compounding/pressing suiteI D) (4) increased from 0.9% in
16)14)
to 24.4% in 4 lbH l with Penicillium and Aspergillus species identified (IR-2025-043). ...
Observation 5
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, your firm failed to perform environmental monitoring as required in SOP 4.090, Environmental and Personnel Monitoring Program, version 7, section 7 .1. This includes data, and evaluation supporting continuous <Redacted B4> non-viable particle sampling in ISO 5 and ISO 7 areas, regardless of batch manufacturing activities.
Observation 6
Test devices are deficient in that instmments not meeting established specifications are used.
Specifically, analytical balance <Redacted B4> calibrations and/or <Redacted B4> verifications do not cover the full bracketed range of use for the pellet process weights <Redacted B4> to <Redacted B4>. For example:
• Analytical balance 19-00003 (serial <Redacted B4> was calibrated on 04/13/2026 at <Redacted B4> to <Redacted B4>. This balance is used for the pellet compounding process in <Redacted B4>
This is a repeat observation
Inspection Jul 7, 2025 to Jul 18, 2025: 5 observations
- Firm on the cover
- Right Value Drug Stores LLC, 8400 Esters Blvd Ste 190, Irving, TX 75063-2217
- FEI number
- 3010589333
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
A. Deviation DEV-2025-166, dated 06/19/2025, reported a high number of dark particulate defects identified during the visual inspection causing a <Redacted B4> major defect percentage in the sterile injectable drug product Testosterone Cypionate 200m ml with Miglyol, lot <Redacted B4> ,BUD 03/31/2026. Your firm identified 41 vials contaminated with dark particulates and 6 vials contaminated with filaments. A total of 60 vials were removed for critical and major defects out <Redacted B4> vials. No investigation was performed to identify the root cause of these dark particulates. In addition, your firm failed to analyze or characterize the dark particles that were recovered during the visual inspection process. Despite the lack of investigation, a total of <Redacted B4> vials were approved and released for distribution on 06/23/2025 by your firm's Quality Unit.
B. ...
Observation 2
Written procedures are not established that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
Specifically,
Your firm does not have validated methods or procedures for assessing the essential physical characteristics of work-in-progress (WIP) pellets stored in the WIP dry cabinet (Asset 19-00390) in the DEA cage. There are no documented validation studies demonstrating that your hormonal pellet manufacturing process consistently produces pellets meeting predetermined specifications and quality attributes after being stored in the WIP cabinet.
This is a repeat observation.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically,
A. Your firm failed to perform smoke study videos of the biological safety cabinets (BSC) in room H300 in a dynamic state. Your current practice is to perform aseptic filling operations in room H300 in both BSCs (19-00133 and 19-00134) simultaneously. However, the smoke study videos provided does not represent the current practice or worst-case scenario of your aseptic filling operations. Additionally, your firm's Smoke Study Evaluation -Vial Removal, GS-2024-001, date 01/06/2025, does not assess airflow visualization while both BSCs are in operation. This is a repeat observation.
This is a repeat observation.
B. On 07/08/2025, we observed your firm's pharmacy technician (designee) perform personnel monitoring sampling <Redacted B4> lot of the pharmacy technicians in both the left and right BSC, located in room H300 after aseptic filling of Testosterone Cypionate 200mg/ml with Miglyol 30ml, lot <Redacted B4>. We observed the pharmacy technician working in the left BSC (19-00134) disinfect their gloves after batch completion but prior to sampling. ...
Observation 4
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Specifically,
A. The IQ,OQ,PQ (Protocol: QUAL-2025-001) for Dry Cabinet Model <Redacted B4> (Asset 19-00390) was inadequate and failed to demonstrate that the equipment perform as intended for its critical function of storing work-in-progress hormonal pellets. The performance qualification conducted on 02/28/2025, documented failing results for PQ Test Case 1 Power Verification testing, which was designed to ensure the dry cabinet maintains required humidity and temperature parameters until the backup generator activates during power failures. The performance qualification documented failing results for PQ Test Case 4 Addition of Beakers Verification test, which was intended to demonstrate that the dry cabinet maintains interior humidity levels when additional items are introduced into the storage environment. The protocol documented after the addition of <Redacted B4> beakers the cabinet did not maintain the set humidity parameter. ...
Observation 5
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing.
Specifically,
According to your firm's Pharmacy Manager and batch record step 10.7.20 and 10.5.20 states "regularly change the needle while filling fill a maximum of <Redacted B4> vials before replacing the needle. If the needle becomes dull before filling <Redacted B4> vials, replace it as needed." However, your firm's batch record fails to adequately verify that this practice is performed consistently. For example, the batch record Testosterone Cypionate/ Testosterone Propionate 200/10 mg/ml with Miglyol 30ml, lot <Redacted B4> BUD 06/11/2026 failed to document the number of filling needles and vent needles replaced during the aseptic filling process. Your firm's Pharmacy Manager acknowledged that needle replacement is performed specifically to reduce the number of potential black particles (likely rubber coring or metal particles) in the sterile drug products and considers this process a critical quality attribute in the manufacturing/filling process. ...
Inspection Jun 7, 2022 to Jun 27, 2022: 10 observations
- Firm on the cover
- Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop, 8400 Esters Blvd Ste 190, Irving, TX 75063-2217
- FEI number
- 3010589333
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
a) Your firm did not perform an investigation into all environmental monitoring excursions that occurred in the ISO 5 Biological Safety Cabinet (SSC), including performing a product impact assessment. The excursions include the following.
i. Lot # <Redacted B4> of Testosterone Cypionate 200mg/mL Injection compounded and asepfically filled on 06/02/2021 -One (1) CFU recovered for an active air sample in the ISO 5 SSC. The organism recovered was identified as Staphylococcus /ugdunensis. The lot was released and distributed <Redacted B4> /30mL vials).
ii. Lot <Redacted B4> of Testosterone Cypionate 200mg/Testosterone Propionate 10mg/mL Injection compounded and aseptically filled on 07/16/2021 -One ( 1) CFU recovered for an active air sample in the ISO 5 SSC. The organism recovered was identified as Penicillium chrysogenum. The lot was released <Redacted B4> 10mL vials) and distributed.
iii. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
a) Your firm does not conduct active viable air sampling in the ISO 5 areas during production of aseptically filled drug products. Active viable air samples are taken after production, when the ISO 5 BSC is empty and the product has already been filled into vials. On 06/07/2022, we watched the QC employee perform active viable air sampling after the production of lot #. <Redacted B4> of Testosterone Cypionate 200mg/Testosterone Propionate 10mg/mL Injection, when the hood was empty and no product was being filled .
Your firm has no documented justification for the orientation of the non-viable particle continuous monitoring probes located in the ISO 5 biological safety cabinets (BSC). The placement of the <Redacted B4> is not fixed and is bumped and moved during production and cleaning of the BSCs. Orientation of the <Redacted B4> is not directed into the flow of air during monitoring. Your firm cannot demonstrate that the orientation and placement of the probes provides a meaningful sample. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Specifically,
b) Your firm has no documentation to show the ISO 5 biological safety cabinets and laminar flow hoods where sterile drug products are <Redacted B4> and filled into vials were certified under dynamic conditions.
c) Your firm does not check the pH nor conduct growth promotion of the media prepared by your firm for use in media fills (aseptic process simulation).
Observation 4
Drug product closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
Specifically, your firm receives in non-sterile <Redacted B4> caps to be used for the packaging of sterile hormone pellets in glass vials. Your firm has no documentation to show that these caps have been cleaned and <Redacted B4> before receipt. Your firm has no process to clean and <Redacted B4> them before use in packaging.
Observation 5
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, the HEPA filter <Redacted B4> used to remove dust from the pellet presses as well as from hormone pellets at the time of vialing are not sanitized approprriately and their design does not allow for adequate storage and protection of the end of the <Redacted B4> that touches the pellets, when not in use. Your firm's written procedure SOP 6.030 Pellet Production, does not provide specific instructions on how to store or protect the end of the <Redacted B4> or what to do if the end of the <Redacted B4> touches the floor. On 06/09/2022 during the vialing of lot <Redacted B4> of Testosterone 200mg pellets, we saw the <Redacted B4> on the HEPA filter <Redacted B4> fall on the floor when the operator tried storing it after use. The <Redacted B4> was not cleaned and sanitized before being used again. The end of the <Redacted B4> touches the pellets through a <Redacted B4> when they are being <Redacted B4>
Observation 6
Batch production and control records do not include dates of each significant step in the manufacture and processing of the batch for each batch of drug product produced.
Specifically, the batch record for Testosterone Cypionate 200mg/Testosterone Propionate 10mg/mL states to <Redacted B4>. For the <Redacted B4> batch, this would equate to approximately <Redacted B4>. Your firm documents the beginning of this <Redacted B4> of mixing <Redacted B4> as the batch record states. For example, for lot # <Redacted B4> it took approximately <Redacted B4> to weigh and add all ingredients. The solution was then mixed for approximately <Redacted B4>. Your firm has no documentation to show that the process has been validated.
Observation 7
Written procedures are lacking which describe in sufficient detail the receipt, identification, sampling, testing, approval and rejection of components.
Specifically, your firm is using a <Redacted B4> to make non-sterile drug products such as dental gels. Your firm does not perform testing (analytical or microbiological) to show the <Redacted B4> at least/at minimum meets the specifications for <Redacted B4>. The quality of the <Redacted B4> is not appropriate for pharmaceutical use.
Observation 8
Specifically,
a) Your firm is not bracketing the range of use when calibrating the analytical balances used to weigh raw materials and perform in process weight checks of hormone pellets. For example, your firm weighs hormone pellets as part of in-process testing and release testing (weight variation). The pellets weigh from <Redacted B4> lowest allowed weight for <Redacted B4> to <Redacted B4> highest weight for <Redacted B4>. There are <Redacted B4> analytical balances used for weighing the pellets. The first test point is <Redacted B4> on <Redacted B4> and <Redacted B4> on <Redacted B4>.
b) Your firm does not have a written procedure or documentation for the calibration of the <Redacted B4> used for non-sterile drug products. <Redacted B4> is an in-process test and can also be part of the release testing for dental gels such as Lidocaine/Prilocaine/Tetracaine/Phenylephrine 10/10/4/2% Aqueous Gel.
Observation 9
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Specifically,
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six-month period. Specifically, the following products were compounded and not identified on your report dated [December 29, 2021 (2021-2)]:
• Benzocaine/Lidocaine HCI/Tetracaine (R&D lot, not distributed)
• Dyclonine HCI/Diphenhydramine HCI (R&D lot, not distributed)
• Ketoconazole/Zinc Oxide topical (R&D lot, not distributed)
• Ketorolac tromethamine/magnesium (R&D lot, not distributed)
• Testosterone 100 mg/Triamcinolone (R&D lot, not distributed)
• Testosterone 12.5 mg with 0.02% Triamcinolone pellets (R&D lot, not distributed)
• Testosterone 50 mg with Triamcinolone (R&D lot, not distributed)
• Testosterone 55 mg with 0.02% Triamcinolone pellets (R&D lot, not distributed)
• Methylprednisolone/Lidocaine 80mg/2.5mg/ml (produced, but not distributed during this time period) ...
Observation 10
The container labels of your outsourcing facility's drug products are deficient.
The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B). Specifically, your containers do not include the following information:
Route of administration.
Examples of drug product containers that do not contain this information:
• Estradiol 20 mg (with 1.6% stearic acid) pellet (Lot <Redacted B4>);
• Testosterone 87.5 mg (with 5.5% stearic acid) pellet (Lot <Redacted B4>) ~)· • Testosterone 100 mg (with 5.5% stearic acid) pellet (Lot # <Redacted B4> and
• Testosterone/Anastrozole 100 mg/5 mg (with 5.5% stearic acid) pellet (Lot <Redacted B4>I).
Inspection Oct 28, 2019 to Nov 12, 2019: 9 observations
- Firm on the cover
- Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop, 8400 Esters Blvd , Suite 190, Irving, TX 75063-2217
- FEI number
- 3010589333
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 4040 North Central Expressway, Suite 300 Dallas, TX 75204
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Specifically,
1. Room certifications conducted on June 22, 2019 by a third-paity vendor established that the firm's ISO7/8 classified rooms all met their intended classifications however, room certifications were performed inadequately because they were conducted at rest and not under dynamic conditions to simulate normal routine production. Approximately <Redacted B4> batches of sterile injectable drugs products have been aseptically filled since June 22, 2019 in your ISO7 buffer rooms containing your ISO 5 hoods.
2. No smoke studies have been conducted to evaluate the unidirectional airflow in the ISO5 LAFHs under dynamic conditions. Approximately <Redacted B4> batches of sterile injectable drug products have been aseptically filled in the ISO5 LAFHs.
3. Your firm failed to properly review the positive pressure of the ISO7 anterooms of your hazardous and non-hazardous sterile suites from 8/19/19 to 10/17/2019. Therefore, your firm was not aware of the consistent loss of pressure until 10/17/2019.
Observation 2
Aseptic processing ai·eas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
Your firm does not follow or record the contact times established by your disinfectant efficacy studies required to effectively clean the ISOS LAFH/BSC and ISO7 buffer, ante and preparation rooms. On 10/28/2019, I observed <Redacted B4> cleaning procedures and obse1ved the ste1ile technician disinfect the ISOS LAFH with the <Redacted B4> immediately wipe dry with a sterile wipe. Your disinfectant efficacy studies state that contact time for <Redacted B4> is <Redacted B4> Therefore, there is no assurance that your cleaning process using various sterile cleaning agents are sufficient to achieve adequate levels of disinfection.
Observation 3
Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component.
Specifically,
Your firm failed to conduct at least one specific identity test for the following drug components in lieu of complete testing when maintaining the supplier's certificate of analysis:
1. Methylcobalamin, Batch/Lot Number <Redacted B4> used in Chodonic Gonadotropin/Methyl-Bl2 l000U/ lmg/lml Injection Lot #09162019@2.
2. Human Chorionic Gonadotropin, USP Batch/Lot Number <Redacted B4> used in Chorionic Gonadotropin/Methyl-B12 l000U/ lmg/lml Injection Lot #09162019@2.
3. Estradiol <Redacted B4>, Batch Number <Redacted B4> used in Estradiol 6mg Pellet, Lot #082819@02.
Observation 4
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
The Quality Control Unit (QCU) failed to thoroughly review batch production records for any unexplained discrepancy. There were batch production records missing specific identification numbers of major equipment used in production, missing pass/fail of ph calibration check, documentation of start times and stop times, incorrect visual examination reconciliation and lack of documentation of positive pressure of the 1S07 buffer and 1S07 preparation rooms. Batch production records with missing information was reviewed and subsequently released by the film's QCU.
Observation 5
Procedures describing the handling of all written and oral complaints regarding a drug product are not established and written.
Specifically,
Your film has a contract with <Redacted B4> to market, advertise and promote your sterile hormone pellets however, your firm has not established specific written procedures to ensure that all complaint received by <Redacted B4> regarding your sterile hormone pellets are forwarded to your firm. Therefore, your firm may not receive all written or oral complaints related to your sterile hormone pellets that need to be further investigated to determine if there are potential quality issues of your drug products and/or reportable to FDA in the event of an adverse drug reaction.
Observation 6
Poor sterile gowning practices may allow sterile garb to become contaminated.
Specifically,
Gowning practices observed on 10/28/2019 by a Sterile Technician and a Quality Control Technician demonstrated that the technicians permit the sterile jump suit to repeatedly touch the floor which may contaminate the sterile jump suit prior to entry of the 1SO7 buffer room containing the ISO 5 LAFH. The practice of allowing the sterile jump suit to repeatedly touch the floor was observed again on 10/29/2019.
Observation 7
Your outsourcing facility has not submitted an adverse event report to FDA in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305 as required by section 503B(b)(5).
Specifically,
On 09/26/2019, the firm received an unexpected possible life-threatening adverse drug reaction from the patient's doctor regarding implementation of the following sterile pellets:
1. Sterile Testosterone Pellet 25mg, Lot #102215-02.
2. Sterile Testosterone Pellet 50mg, Lot #101415-02.
3. Sterile Testosterone Pellet 87.5mg, Lot #1 02215-12.
As of 10/31/2019, the adverse event reaction to these drug products have not been reported to FDA within 15 calendar days from 09/26/2019 required.
Observation 8
You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503(B)(d)(2).
Specifically, you compound drug products that
a) are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, distiibution, and dispensing; or
b) are not identical or nearly identical to an approved drug but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.
Examples of compounded drug products that are essentially a copy of one or more approved drugs include:
1. Dyclonine (mint) * Office Use* 0.5% Solution
2. Dyclonine (mint) * Office Use* 1 % Solution
Observation 9
Your outsourcing facility has not submitted a report to FDA identifying products compounded during the previous six months as required by section 503B(b)(2)(A). Specifically, the following products were compounded and not identified on your report dated July 3, 2019:
4. HCG Methylcobalamin B12 1000IU Injection
5. Testosterone Pellets-25mg, 37.5mg, 50mg, 100mg and 200mg
6. Estradiol Pellets -6mg, 10mg, 12.5mg and 15mg
7. Testosterone/Anastrozole Pellets -75mg/4mg, 100mg/4mg
8. Testosterone cypionate/ Testosterone propionate 200mg/10mg Injection
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Right Value Drug Stores, LLC, dba Carie Boyd's Prescription Shop). That is not a finding beyond this index’s search.
The Right Value Drug Stores, LLC, dba Carie Boyd's Prescription Shop pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.